Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Immune checkpoint inhibitors vs any second‐line chemotherapy

Time to progression · participants with advanced or metastatic muscle invasive bladder cancer

It is very uncertain whether immune checkpoint inhibitors changes time to disease progression Range of compared with any second‐line chemotherapy (very low certainty).

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
HR 0.99 [0.84, 1.16]
2 studies · 1473 participants
Very low

Immune checkpoint inhibitors vs any first‐line chemotherapy

Time to progression · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors probably leads to higher time to disease progression Range of compared with any first‐line chemotherapy (moderate certainty).

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
HR 1.33 [1.17, 1.5]
2 studies · 1349 participants
Moderate